<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03666546</url>
  </required_header>
  <id_info>
    <org_study_id>Lact-004-CP4</org_study_id>
    <secondary_id>2018-002359-14</secondary_id>
    <nct_id>NCT03666546</nct_id>
  </id_info>
  <brief_title>Blood Glucose Response After Oral Intake of Lactulose in Mildly Constipated Patients With Diabetes Mellitus Type 2</brief_title>
  <official_title>Blood Glucose Response After Oral Intake of Lactulose (Laevolac®) in Mildly Constipated Patients With Diabetes Mellitus Type 2</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fresenius Kabi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fresenius Kabi</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the study is to investigate whether lactulose, given orally as powder or
      liquid, increases blood glucose levels in patients with diabetes mellitus type 2. The dose of
      lactulose given in the study is normally used for treatment of constipation.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 26, 2018</start_date>
  <completion_date type="Actual">March 8, 2019</completion_date>
  <primary_completion_date type="Actual">March 5, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Capillary blood glucose levels as baseline corrected AUC: AUCbaseline_c (0-180 minutes) [Baseline corrected area under curve from 0 to 180 minutes for blood glucose concentration (= Area under curve from 0 to 180 minutes minus baseline*180 minutes)]</measure>
    <time_frame>0 - 180 minutes, during 4 study visits</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum blood glucose concentration (Cmax)</measure>
    <time_frame>0 - 180 minutes, during 4 study visits</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum increase of blood glucose concentration (Max_increase)</measure>
    <time_frame>0 - 180 minutes, during 4 study visits</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relative maximum increase of blood glucose concentration (Max_increase_rel)</measure>
    <time_frame>0 - 180 minutes, during 4 study visits</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to reach maximum blood glucose concentration (Tmax)</measure>
    <time_frame>0 - 180 minutes, during 4 study visits</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total area under curve from 0 to 180 minutes for blood glucose concentration (AUC(0-180 minutes))</measure>
    <time_frame>0 - 180 minutes, during 4 study visits</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incremental area under curve from 0 to 180 minutes for blood glucose concentration, i.e., above baseline levels for blood glucose concentration after oral intake of Laevolac crystals/liquid or control products (iAUC(0-180min))</measure>
    <time_frame>0 - 180 minutes, during 4 study visits</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Adverse Events (AEs)</measure>
    <time_frame>up to 64 days</time_frame>
    <description>Adverse Events will be documented from start of fasting on the day before Screening until the day after the last study Intervention. This is up to 64 days, depending on the day of Screening (21 to 3 days before the first study Intervention) and on the duration of wash out phases between interventions.</description>
  </other_outcome>
  <other_outcome>
    <measure>Gastrointestinal tolerability: global scaled evaluation</measure>
    <time_frame>180 minutes and 24 hours post-dose</time_frame>
    <description>Gastrointestinal tolerability will be assessed by the patients by means of a global scaled evaluation with &quot;Very good&quot;, &quot;Good&quot;, &quot;Moderate&quot;, or &quot;Poor&quot;.</description>
  </other_outcome>
  <other_outcome>
    <measure>Gastrointestinal tolerability: diarrhoea, distension, rumbling, nausea, vomiting, burping, regurgitation/heartburn, flatulence, abdominal discomfort, abdominal pain</measure>
    <time_frame>180 minutes and 24 hours post-dose</time_frame>
    <description>The single gastrointestinal symptoms will be assessed by the patients using a 4-point Likert scale: &quot;No symptoms or discomfort&quot;, &quot;Mild symptoms or discomfort&quot;, &quot;Moderate symptoms of discomfort&quot;, or &quot;Severe symptoms of discomfort&quot;.</description>
  </other_outcome>
  <other_outcome>
    <measure>Blood glucose concentration at 240 minutes - only when blood glucose is &gt;10 mmol/L (&gt;180 mg/dL) at 180 minutes</measure>
    <time_frame>240 minutes post-dose</time_frame>
  </other_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>Laevolac crystals 20 g</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lactulose crystals, oral intake, 20 g single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Laevolac crystals 30 g</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lactulose crystals, oral intake, 30 g single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Laevolac liquid 20 g</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lactulose liquid, oral intake, 20 g single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Laevolac liquid 30 g</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lactulose liquid, oral intake, 30 g single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Glucose 30 g</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Glucose Monohydrate, oral intake, 33 g single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Water</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Still water, oral intake, 250 mL single dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lactulose crystals 20 g</intervention_name>
    <description>White or almost white crystalline powder. The product will be provided in sachets to be dissolved in 250 mL water.</description>
    <arm_group_label>Laevolac crystals 20 g</arm_group_label>
    <other_name>Laevolac crystals 20 g</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lactulose crystals 30 g</intervention_name>
    <description>White or almost white crystalline powder. The products will be provided in sachets to be dissolved in 250 mL water.</description>
    <arm_group_label>Laevolac crystals 30 g</arm_group_label>
    <other_name>Laevolac crystals 30 g</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lactulose liquid 20 g</intervention_name>
    <description>Clear, viscous liquid, colourless or pale brownish-yellow liquid syrup (solution). The products will be provided in sachets to be dissolved in 250 mL water.</description>
    <arm_group_label>Laevolac liquid 20 g</arm_group_label>
    <other_name>Laevolac liquid 20 g</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lactulose liquid 30 g</intervention_name>
    <description>Clear, viscous liquid, colourless or pale brownish-yellow liquid syrup (solution). The products will be provided in sachets to be dissolved in 250 mL water.</description>
    <arm_group_label>Laevolac liquid 30 g</arm_group_label>
    <other_name>Laevolac liquid 30 g</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glucose</intervention_name>
    <description>White crystalline powder. To standardise for 30 g glucose, 33 g glucose monohydrate will be used. The products will be provided in sachets to be dissolved in 250 mL water.</description>
    <arm_group_label>Glucose 30 g</arm_group_label>
    <other_name>Glucose Monohydrate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Still water</intervention_name>
    <description>250 mL still water will be used. Water from the same source will be also used to dissolve investigational and control products</description>
    <arm_group_label>Water</arm_group_label>
    <other_name>Water</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients with non-insulin requiring diabetes mellitus type 2 treated with diet and
             oral antidiabetics and/or Glucagon-like Peptide 1 receptor agonists

          2. Age: 18-75 years

          3. Female and male

          4. Caucasian

          5. HbA1c ≤ 7.5 %

          6. Stable treatment, i.e. no change in diabetes mellitus related medication within the
             last 3 months

          7. Mild functional constipation according to modified Rome IV criteria fulfilled for the
             last 3 months with symptom onset at least 6 months before study start defined as:

               -  approx. 3-5 bowel movements per week,

               -  of which 1-2 usually cause discomfort e.g., straining, lumpy or hard stools,
                  sensation of incomplete evacuation or anorectal obstructions/blockage

          8. Availability and presence in the trial unit for approx. 4 hours/ week for 4 weeks

          9. Women of childbearing potential must be using a medically approved method of
             contraception OR women must be postmenopausal for at least 12 months prior to study
             entry

         10. Signed informed consent form

        Exclusion Criteria:

          1. Fasting blood glucose &lt;4.4 mmol/L (&lt;80 mg/dL) or &gt;10 mmol/L (&gt;180 mg/dL) (capillary)

          2. BMI &lt;18.5 kg/m² or ≥35 kg/m²

          3. Change in body weight ≥10 % within the last 3 months

          4. Smoker

          5. Major medical or surgical event requiring hospitalization within the last 3 months

          6. Acute gastrointestinal diseases including diarrhea and/or vomiting within the last 2
             weeks

          7. Presence of disease or intake of drug(s) / supplements other than antidiabetic
             treatment influencing digestion and absorption of carbohydrates or bowel habits
             (intake of laxatives in general allowed with exception see next criterion) (dietary /
             supplementary fibres allowed if stable dose since 1 month before study start)

          8. Not willing to abstain from laxatives 2 days before the visits 1-4 and up to 24h after
             visits 1-4

          9. Use of following medication/ supplementation within the last 4 weeks and during the
             study:

               -  Intake of medications other than antidiabetic treatment known to affect glucose
                  tolerance e.g., steroids, protease inhibitors or antipsychotics;

               -  Intake of prebiotics or probiotics

               -  Chronic intake of substances affecting blood coagulation (e.g. acetylic acid (100
                  mg as standard prophylactic treatment allowed when dose is stable 1 month prior
                  to screening), anticoagulants, diuretics, thiazides (diuretics and thiazides
                  allowed e.g. for hypertension treatment when dose is stable 1 month prior to
                  screening)), which in the investigator's opinion would impact patient safety

         10. Severe liver, renal or cardiac disease

         11. Hereditary problems of galactose or fructose intolerance, lactase deficiency or
             glucose-galactose malabsorption

         12. Suspicion of alcohol abuse (defined as an average daily intake of more than one litre
             of beer per day or equivalent amount of alcohol in other beverages) or drug abuse

         13. Known or suspected allergy to the investigational drug(s) or other components of the
             study drug(s)

         14. Acute inflammatory bowel disease (ulcerative colitis, Crohn's disease),
             gastrointestinal obstruction or subocclusive syndrome, perforations or risk of
             perforation in gastrointestinal tract, abdominal pain of undetermined cause

         15. Known history of human immunodeficiency virus (HIV), hepatitis B and/or C

         16. Pregnancy, lactation

         17. Clinically relevant findings as established by medical history, physical examination,
             clinical laboratory and/or vital signs

         18. Participation in another interventional study with an investigational drug or an
             investigational medical device within 30 days prior to start of study or during the
             study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas Pieber, Prof. MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Head and Chair of Department of Internal Medicine, Division of Endocrinology and Diabetology, Medical University, Graz, Austria</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinical Research Center (CRC)</name>
      <address>
        <city>Graz</city>
        <zip>A-8036</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>August 23, 2018</study_first_submitted>
  <study_first_submitted_qc>September 10, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 12, 2018</study_first_posted>
  <last_update_submitted>April 11, 2019</last_update_submitted>
  <last_update_submitted_qc>April 11, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 12, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Blood glucose</keyword>
  <keyword>Diabetes Mellitus, Type 2</keyword>
  <keyword>Lactulose</keyword>
  <keyword>Constipation</keyword>
  <keyword>Oral intake</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methamphetamine</mesh_term>
    <mesh_term>Lactulose</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

